The tweet was deleted by the author.
But we saved everything 🙂.
Outlook Therapeutics has announced the resubmission of its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg), a therapy candidate aimed at treating retina diseases such as wet age-related macular degeneration.
This move comes amid growing demand for new treatments in ophthalmology, with ONS-5010 potentially providing an alternative option for patients suffering from vision impairment related to retinal conditions. The U.S. FDA review will determine whether ONS-5010 can move forward toward market approval.
Outlook Therapeutics recently launched a registered direct offering priced at the market under Nasdaq rules. Earlier this year, the company won an appeal tied to ONS-5010 LYTENAVA through a formal dispute resolution process. These developments have supported ongoing product progress.